![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
The ability to switch between yeast and hyphal growth forms (dimorphism) is one of the most discussed and best investigated virulence attributes of the human pathogenic fungus Candida albicans. Both morphological forms seem to be important for virulence and have distinct functions during the different stages of disease development, including adhesion, invasion, damage, dissemination, immune evasion and host response. In this review, we will provide an overview of the known and potential roles of C. albicans dimorphism and will discuss the potential benefit of drugs that can inhibit the morphological transition.
Financial & competing interests disclosure
The authors’ research is supported by the Hans Knöll-Institut, the Federal Ministry of Education and Research (BMBF: ERA Net PathoGenoMics FUNPath 0313931B and CandiCol 0315901B, PET-CT 0314108, Integrated Research and Treatment Center, Sepsis und Sepsisfolgen, Center for Sepsis Control and Care), the Deutsche Forschungsgemeinschaft (DFG Hu 528/14, 15, 16 and 17), the European Union (CaInfectome PIEF-GA-2008-219406, FinSysB MCRTN FP7-214004), the companies Biolitec and Bayer Vital, NIDCR (DE017514; to JR Naglik) and the Department of Health via the National Institute for Health Research comprehensive Biomedical Research Centre award to Guy’s & St Thomas’ NHS Foundation Trust in partnership with King’s College London (to JR Naglik). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.